Hip fracture prevention: Drug therapies and lifestyle modifications that can reduce risk

Postgraduate Medicine

Volumn 114, Issue 3, 2003, Pages

  Fiechtner, Justus J ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLECALCIFEROL; ESTROGEN; GESTAGEN; IPRIFLAVONE; ISOFLAVONE; PARATHYROID HORMONE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

BONE MASS; BONE TURNOVER; CLINICAL TRIAL; CONFERENCE PAPER; COST; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; ENVIRONMENT; EXERCISE; FALLING; HAZARD; HEALTH PROGRAM; HIP FRACTURE; HORMONE SUBSTITUTION; HOSPITAL COST; HUMAN; INCIDENCE; LIFESTYLE; MEDICAL CARE; META ANALYSIS; MONITORING; MORBIDITY; MORTALITY; OSTEOLYSIS; OSTEOPOROSIS; PHYSICAL ACTIVITY; POSTMENOPAUSE; PROPHYLAXIS; RISK; SUPPLEMENTATION; THROMBOSIS; TREATMENT OUTCOME; VITAMIN INTAKE; WEIGHT BEARING;

EID: 0141707132     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2003.09.1489     Document Type: Conference Paper

References (41)

1. Cumming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. Epidemiol Rev 1997;19(2):244-57
2. Melton LJ III, Thamer M, Ray NF, et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12(1):16-23
3. Walker N, Norton R, Vander Hoorn S, et al. Mortality after hip fracture: regional variations in New Zealand. N Z Med J 1999;112(1092):269-71
4. Koot VC, Peeters PH, de Jong JR, et al. Functional results after treatment of hip fracture: a multicentre, prospective study in 215 patients. Eur J Surg 2000;166(6):480-5
5. Jalovaara P, Virkkunen H. Quality of life after primary hemiarthroplasty for femoral neck fracture: 6-year follow-up of 185 patients. Acta Orthop Scand 1991;62(3):208-17
6. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12(1):24-35
7. Gallagher TC, Geling O, Comite F. Missed opportunities for prevention of osteoporotic fracture. Arch Intern Med 2002;162(4):450-6
8. Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994;331(13):821-7
9. Kannus P, Parkkari J, Niemi S, et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 2000;343(21):1506-13
10. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000;15(6):1113-8
11. 3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327(23):1637-42
12. Snow CM, Shaw JM, Winters KM, et al. Long-term exercise using weighted vests prevents hip bone loss in postmenopausal women. J Gerontol A Biol Sci Med Sci 2000;55(9):M489-91
13. Kujala UM, Kaprio J, Kannus P, et al. Physical activity and osteoporotic hip fracture risk in men. Arch Intern Med 2000;160(5):705-8
14. Rutherford OM. Is there a role for exercise in the prevention of osteoporotic fractures? Br J Sports Med 1999;33(6):378-86
15. Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002;97(1):58-64
16. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282(14):1344-52
17. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11(1):83-91
18. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344(5):333-40
19. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-41
20. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280(24): 2077-82
21. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333(22):1437-43
22. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999;9(5):461-8
23. Cauley JA, Black DM, Barrett-Connor E, et al. Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen/progestin Replacement Study (HERS). Am J Med 2001;110(6):442-50
24. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282(7):637-45
25. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence Of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000;109(4):267-76
26. Riggs BL, Melton LJ III. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002;17(1):11-4
27. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000;11 Suppl 6:S2-17
28. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85(11):4118-24
29. Geusens P, Adami S, Bensen W, et al. Risedronate reduces risk of hip fracture in elderly women with osteoporosis. (Abstr S67) Presented at the 27th European Symposium on Calcified Tissue, 2000, Tampere, Finland
30. Watts NB, Sorensen O, Eriksen E, et al. Risedronate therapy for postmenopausal osteoporosis reduces vertebral and nonvertebral fractures after 5 years and results in normal bone histology. (Poster) Presented at the American College of Rheumatology 65th Annual Scientific Meeting, Nov 10-15, 2001, San Francisco
31. Bolognese M, Fogelman I, Guesens P, et al. Risedronate significantly reduces the risk of non-vertebral fractures in postmenopausal osteoporotic women in just one year. (Abstr) J Bone Miner Res 2001;16:S404
32. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285(22):2891-7
33. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33
34. Pilon D, Castilloux AM, LeLorier J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet Gynecol 2001;97(1):97-100
35. Arjmandi BH, Birnbaum RS, Juma S, et al. The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms. Calcif Tissue Int 2000;66(1):61-5
36. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 2001;285(6):785-95
37. Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997;82(2): 620-8
38. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344(19):1434-41
39. Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000;283(10): 1318-21
40. Watts N, Sarkar S, Wu W, et al. Validation of change in bone mineral density as a surrogate for fracture risk after statistical adjustment for imprecision in bone mineral density measurements. (Abstr) Bone 2001;28:S93
41. Looker AC, Bauer DC, Chesnut CH III, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 2000;11(6):467-80